Literature DB >> 11694116

Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.

J T Barbey, S Soignet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11694116     DOI： 10.7326/0003-4819-135-9-200111060-00021

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  4 in total

Review 1.  Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.

Authors:  Tarsheen K Sethi; Basak Basdag; Nirmanmoh Bhatia; Javid Moslehi; Nishitha M Reddy
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

Review 2.  Is Arsenic Exposure a Risk Factor for Metabolic Syndrome? A Review of the Potential Mechanisms.

Authors:  Pablo Pánico; Myrian Velasco; Ana María Salazar; Arturo Picones; Rosa Isela Ortiz-Huidobro; Gabriela Guerrero-Palomo; Manuel Eduardo Salgado-Bernabé; Patricia Ostrosky-Wegman; Marcia Hiriart
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-16       Impact factor: 6.055

3.  Resveratrol protects against arsenic trioxide-induced cardiotoxicity in vitro and in vivo.

Authors:  X-Y Zhao; G-Y Li; Y Liu; L-M Chai; J-X Chen; Y Zhang; Z-M Du; Y-J Lu; B-F Yang
Journal:  Br J Pharmacol       Date:  2008-03-10       Impact factor: 8.739

4.  QTc prolongation assessment in anticancer drug development: clinical and methodological issues.

Authors:  G Curigliano; G Spitaleri; F de Braud; D Cardinale; C Cipolla; M Civelli; N Colombo; A Colombo; M Locatelli; A Goldhirsch
Journal:  Ecancermedicalscience       Date:  2009-01-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.